Drug discovery > Basic Research Products & Reviews

Twist Biopharma, a division of Twist Bioscience, provides services to help accelerate the way our partners discover and optimize antibody therapeutics with our unique DNA writing technology. Twist constructs proprietary antibody libraries precisely designed to match sequences that occur in the human body giving our partners an integral and unbiased resource for antibody therapeutic discovery and optimization.

Twist also offers Research-Use Only (RUO) target enrichment NGS panels for viral detection and characterization of samples. These panels can be used for environmental monitoring and surveillance testing, while also providing insight into full sequence information for monitoring of viral evolution and strain origin.

The superior performance of Twist Human Core Exome provides the optimal solution for sequencing of protein coding genes. The Twist Human Core Exome however focuses only on the most accurate curated subset—CCDS database. Twist now offers the Twist Human RefSeq Panel, which is designed to expand the content of the Twist Human Core Exome. When combining the two panels, greater than 99% of protein coding genes are covered.

Twist Library Preparation Kit (Mechanical Fragmentation) is designed for use with gDNA that has already been sheared mechanically. It combines the enzymes and reagents for end repair, dA-tailing, and adapter ligation into a single reaction: Accommodates a wide range of DNA input types, enables high-quality sequencing of low-quality samples and minimizes start / stop site artifacts

Twist Library Preparation EF Kit (Enzymatic Fragmentation) incorporates the reagents and enzymes needed for DNA fragmentation with those for end repair, dA-tailing, and adapter ligation into a single reaction:  Ideal for automated, high-throughput library preparation, produces tunable, reproducible fragment sizes and minimizes sequence bias, maximizes coverage depth.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity.  Several antibodies also show the ability to block S1 binding to ACE2.

Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity.  Several antibodies also show the ability to block S1 binding to ACE2.

The Twist 96-Plex Library Preparation kit enables high-throughput library construction for whole genome sequencing. 

The Twist Alliance CeGaT RNA Fusion Panel is a targeted RNA sequencing solution designed to detect both known and novel gene fusions across 160 genes associated with over 30 cancer types, enhancing cancer and precision medicine research.

Twist Exome 2.0 is a comprehensive exome sequencing panel designed to detect rare and inherited diseases, as well as germline cancers. Its high uniformity and low off-target rate deliver best-in-class sequencing efficiency, enabling quality data collection with less sequencing.

For best-in-class results, use best-in-class tools